22.418 makale bulundu

SYNUCLEINOPATHIC VE AMYLOIDOGENIC HASTALIKLARININ ÖNCELENMESİ VE TEDAVİSİ

PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE

SCHENK DALE B, MASLIAH ELIEZER, GAMES KATE DORA, CHILCOTE TAMIE J, ROCKENSTEIN EDWARD, BUTTINI MANUEL J.

· 2008-02-22

Terapötik derin beyin stimülasyonu sırasında palidal patlama aktivitesi.

Pallidal burst activity during therapeutic deep brain stimulation.

Hahn PJ, Russo GS, Hashimoto T, Miocinovic S, Xu W, McIntyre CC, Vitek JL.

Exp Neurol · 2008-02-20

DOI: 10.1016/j.expneurol.2008.01.032PMID: 18355810

Parkinson hastalığında subtalamik çekirdek stimülasyonu ve levodopa dirençli postural istikrarsızlık.

Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease.

Visser JE, Allum JH, Carpenter MG, Esselink RA, Speelman JD, Borm GF, Bloem BR.

J Neurol · 2008-02-18

DOI: 10.1007/s00415-008-0636-xPMID: 18274810

Parkinson hastalığının tedavisinde entacapone uzun süreli retansiyon oranı.

Long-term retention rate of entacapone in the treatment of Parkinson's disease.

Keränen T, Tuhkasaari M, Kuusisto H.

Eur J Neurol · 2008-02-16

DOI: 10.1111/j.1468-1331.2008.02068.xPMID: 18284429

Levodopa ve enteral beslenme arasındaki etkileşim.

Interaction between levodopa and enteral nutrition.

Cooper MK, Brock DG, McDaniel CM.

Ann Pharmacother · 2008-02-13

DOI: 10.1345/aph.1k450PMID: 18272698

Parkinson hastalığı: levodopa kaynaklı diskinezi ve sinyal transdüksiyonu.

Parkinson's disease: levodopa-induced dyskinesia and signal transduction.

Santini E, Valjent E, Fisone G.

FEBS J · 2008-02-12

DOI: 10.1111/j.1742-4658.2008.06296.xPMID: 18279379

Parkinson hastalığı: Derin beyin stimülasyonu (DBS) ve duodenal levodopa infüzyonuna odaklanan ileri hastalık tedavilerinde son gelişme.

Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.

Sydow O.

FEBS J · 2008-02-12

DOI: 10.1111/j.1742-4658.2008.06295.xPMID: 18279380

Parkinson hastalığının rotenon modelinde davranış değişiklikleri: sentrofenoksinin ko-tedavisi ile zayıflama.

Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.

Nehru B, Verma R, Khanna P, Sharma SK.

Brain Res · 2008-02-09

DOI: 10.1016/j.brainres.2008.01.074PMID: 18308296

Parkinson hastalığı olan hastalarda levodopa/DDCI ve entakaponun beş yıllık etkinliği ve güvenliği.

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

Brooks DJ, Leinonen M, Kuoppamäki M, Nissinen H.

J Neural Transm (Vienna) · 2008-02-08

DOI: 10.1007/s00702-008-0025-8PMID: 18259682

1,5-DIARYL-PYRAZOLES AS CANNABINOID RECEPTOR NEUTRAL ANTAGONİSTLER TERAPOTİK AJENLER kadar YARARLI

1,5-DIARYL-PYRAZOLES AS CANNABINOID RECEPTOR NEUTRAL ANTAGONISTS USEFUL AS THERAPEUTIC AGENTS

GREIG IAIN ROBERT, ROSS RUTH ALEXANDRA, PERTWEE ROGER GUY.

· 2008-02-07

1,5-Diaryl-Pyrazoles Kannabinoid Reseptör Nötr Antagonistler Olarak Terapötik Ajanlar Olarak Faydalı

1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents

GREIG IAIN ROBERT, ROSS RUTH ALEXANDRA, PERTWEE ROGER GUY.

· 2008-02-07

5-HT1B reseptörünün ve uyarlayıcı proteininin rolüne dair kanıtlar, p11, Parkinsonizm'in bir hayvan modelinin L-DOPA tedavisinde.

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.

Zhang X, Andren PE, Greengard P, Svenningsson P.

Proc Natl Acad Sci U S A · 2008-02-06

DOI: 10.1073/pnas.0711839105PMID: 18256188